TLX Stock Analysis: Buy, Sell, or Hold?
TLX - Telix Pharmaceuticals Limited American Depositary Shares
$9.89
-0.17 (-1.69%)
▼
5d:
-3.23%
30d:
-16.47%
90d:
-10.09%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Jul 02, 2026
0d
Get Alerted When TLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: TLX shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: TLX shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$12.62
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$7.84
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TLX is currently trading at $9.89, which is considered oversold relative to its 30-day fair value range of $10.27 to $11.55. From a valuation perspective, the stock is trading at a premium (Forward PE: 38.1) compared to its historical average (27.1). At these levels, the market is pricing in 12.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TLX is in a strong downtrend. The price is currently testing key support at $9.79. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $21.01 (+112.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TLX is in a strong downtrend. The price is currently testing key support at $9.79. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $21.01 (+112.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$10.27 -
$11.55
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
78.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 112.4% below Wall St target ($21.01)
- NEUTRAL: Trading at premium valuation - market expects 12.1% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$10.27 -
$11.55
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$9.79
Resistance Level
$10.92
Current Trend
Strong Downtrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
38.14
Wall Street Target
$21.01
(+112.4%)
Revenue Growth (YoY)
49.3%
Profit Margin
-0.9%
Valuation Premium vs History
+12.1% premium
PE vs Historical
38.1 vs 27.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+12.1%
(market-implied from PE analysis)
1-Year Target
$11.09
(+12%)
2-Year Target
$12.43
(+26%)
3-Year Target
$13.93
(+41%)
3-Yr Target (if PE normalizes)
(PE: 38→27)
PE COMPRESSION
$9.90
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 38.1, Growth: 260.1%)
$33.38
(+238%)
Base:
(SPY PE: 20.7, Growth: 260.1%)
$18.14
(+83%)
Bear:
(PE: 17.6, Growth: 260.1%)
$15.42
(+56%)
Share & Embed Analysis
Last updated: August 02, 2026 11:20 PM ET
Data refreshes hourly during market hours. Next update: 12:20 AM
Data refreshes hourly during market hours. Next update: 12:20 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 53 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 57 HOLD |
